Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

FORENSIC FLUIDS LABORATORIES INC.

NPI: 1023269313 · KALAMAZOO, MI 49007 · Clinical Medical Laboratory · NPI assigned 10/04/2008

$10.23M
Total Medicaid Paid
233,443
Total Claims
158,693
Beneficiaries
38
Codes Billed
2018-01
First Month
2024-12
Last Month

Provider Details

Authorized OfficialLEMBERG, BRIDGET (LAB DIRECTOR)
NPI Enumeration Date10/04/2008

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 71,485 $1.16M
2019 37,039 $971K
2020 16,855 $807K
2021 19,592 $1.27M
2022 26,410 $1.92M
2023 32,855 $2.13M
2024 29,207 $1.97M

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 47,297 38,470 $4.10M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 79,795 60,423 $2.89M
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 14,949 11,778 $1.65M
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 12,146 9,346 $965K
80299 2,079 1,118 $191K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 1,090 850 $115K
80369 5,158 2,289 $30K
80373 5,745 2,641 $28K
80346 5,566 2,482 $28K
80361 5,802 2,666 $27K
80329 4,446 2,165 $26K
80324 5,802 2,683 $24K
80354 5,762 2,642 $22K
80365 5,778 2,656 $22K
80358 5,763 2,646 $21K
80353 5,771 2,657 $21K
80348 5,489 2,466 $21K
80356 5,705 2,628 $20K
80338 1,373 713 $5K
80332 1,058 588 $4K
80342 493 290 $3K
80355 1,123 761 $3K
80362 1,041 404 $3K
80339 722 496 $2K
80375 303 238 $2K
80366 606 459 $2K
80368 551 408 $1K
80370 493 345 $1K
80349 194 158 $1K
80323 336 266 $916.81
80347 120 119 $874.55
80143 93 78 $856.79
83992 178 168 $743.13
80357 128 122 $532.00
80345 137 132 $506.56
80367 121 115 $486.51
80371 114 113 $417.90
80350 116 114 $417.90